Pier Luigi Zinzani

Research interests

Publications

• Immune effector cell–associated hematotoxicity: EHA/EBMT consensus grading and best practice recommendations

  Blood · 2023 · https://doi.org/10.1182/blood.2023020578

• The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee

  Blood · 2022 · https://doi.org/10.1182/blood.2022015851

• Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non–Germinal Center B-Cell Diffuse Large B-Cell Lymphoma

  Journal of Clinical Oncology · 2019 · https://doi.org/10.1200/jco.18.02403

• Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial

  The Lancet · 2018 · https://doi.org/10.1016/s0140-6736(18)32984-2

• International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease

  Blood · 2018 · https://doi.org/10.1182/blood-2018-07-862334

• Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial

  The Lancet Oncology · 2018 · https://doi.org/10.1016/s1470-2045(18)30379-6

• The PROCLIPI international registry of early‐stage mycosis fungoides identifies substantial diagnostic delay in most patients

  British Journal of Dermatology · 2018 · https://doi.org/10.1111/bjd.17258

• Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial

  The Lancet · 2017 · https://doi.org/10.1016/s0140-6736(17)33108-2

• Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin’s Lymphoma

  New England Journal of Medicine · 2017 · https://doi.org/10.1056/nejmoa1708984

• Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial

  The Lancet · 2017 · https://doi.org/10.1016/s0140-6736(17)31266-7

• International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017)

  Annals of Oncology · 2017 · https://doi.org/10.1093/annonc/mdx097

• Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial

  The Lancet · 2017 · https://doi.org/10.1016/s0140-6736(17)31266-7

• Phosphatidylinositol 3-Kinase Inhibition by Copanlisib in Relapsed or Refractory Indolent Lymphoma

  Journal of Clinical Oncology · 2017 · https://doi.org/10.1200/jco.2017.75.4648

• Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia

  Blood · 2016 · https://doi.org/10.1182/blood-2016-01-689422

• Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia

  New England Journal of Medicine · 2015 · https://doi.org/10.1056/nejmoa1506583

• PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma

  New England Journal of Medicine · 2014 · https://doi.org/10.1056/nejmoa1314583

• ESMO Consensus conferences: guidelines on malignant lymphoma. part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma

  Annals of Oncology · 2013 · https://doi.org/10.1093/annonc/mds643

• ABVD versus BEACOPP for Hodgkin's Lymphoma When High-Dose Salvage Is Planned

  New England Journal of Medicine · 2011 · https://doi.org/10.1056/nejmoa1100340

• CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group

  The Lancet Oncology · 2011 · https://doi.org/10.1016/s1470-2045(11)70235-2

• Bortezomib plus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 Trial.

  The Lancet Oncology · 2011 · https://doi.org/10.1016/s1470-2045

• Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial

  The Lancet · 2010 · https://doi.org/10.1016/s0140-6736(10)61381-5

• Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial Group (MInT) study

  The Lancet Oncology · 2008 · https://doi.org/10.1016/s1470-2045(08)70078-0

• Gene Expression Analysis of Angioimmunoblastic Lymphoma Indicates Derivation from T Follicular Helper Cells and Vascular Endothelial Growth Factor Deregulation

  Cancer Research · 2007 · https://doi.org/10.1158/0008-5472.can-07-1708

• CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group

  The Lancet Oncology · 2006 · https://doi.org/10.1016/s1470-2045(06)70664-7

• Myeloid sarcoma: clinico-pathologic, phenotypic and cytogenetic analysis of 92 adult patients

  Leukemia · 2006 · https://doi.org/10.1038/sj.leu.2404491

• Follicular lymphoma international prognostic index.

  PubMed · 2004 · https://doi.org/10.1182/blood-2003-12-4434

• Nongastric marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue

  Blood · 2003 · https://doi.org/10.1182/blood-2002-04-1279

• T(11;18) is a marker for all stage gastric MALT lymphomas that will not respond to H. pylori eradication

  Gastroenterology · 2002 · https://doi.org/10.1053/gast.2002.33047

• ALK+ lymphoma: clinico-pathological findings and outcome.

  PubMed · 1999 · https://doi.org/10.1182/blood.v93.8.2697

Current projects

No projects listed.